---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009731"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:08:53.252983+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics reports preclinical data: systemic RTNova platform delivers gene therapy payload to tumors

## Summary
- RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.
- Single dose of 3KO RT with immunotherapeutic payload increased leukocyte infiltration to 92% vs 46% untreated.
- Complete eradication of certain tumors observed in preclinical model after treatment with 3KO RT plus payload.
- Platform also acts as a viral vector to express therapeutic genes at tumor sites; potential partnerships noted.

## SEC filing metadata
- accession: 0001493152-25-009731
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225009731/0001493152-25-009731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225009731/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009731
- JSON: https://secwatch.observer/filing/0001493152-25-009731.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.